Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Saved in:
| Title: | Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. |
|---|---|
| Authors: | Huber H; Sektion CLL, Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany.; Medizinische Klinik III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany., Tausch E; Sektion CLL, Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany., Schneider C; Sektion CLL, Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany., Edenhofer S; Sektion CLL, Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany., von Tresckow J; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany.; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Robrecht S; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Giza A; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Zhang C; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Fürstenau M; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Dreger P; Department Medicine V, University of Heidelberg, Heidelberg, Germany., Ritgen M; Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Illmer T; Group Practice for Hematology and Oncology, Dresden, Germany., Illert AL; Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Dürig J; Deptartment of Internal Medicine, St. Josef Krankenhaus Werden, University Medicine Essen, Essen, Germany., Böttcher S; Medizinische Klinik III, Universitätsklinikum Rostock, Rostock, Germany., Niemann CU; Department of Clinical Medicine, Rigshospitalet, Copenhagen, Denmark., Kneba M; Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Germany., Al-Sawaf O; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Kreuzer KA; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Fink AM; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Döhner H; Sektion CLL, Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany., Hallek M; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Eichhorst B; Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany., Stilgenbauer S; Sektion CLL, Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany. |
| Source: | Blood [Blood] 2023 Sep 14; Vol. 142 (11), pp. 961-972. |
| Publication Type: | Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
